Subtopic Deep Dive

Group B Streptococcus Neonatal Sepsis
Research Guide

What is Group B Streptococcus Neonatal Sepsis?

Group B Streptococcus (GBS) neonatal sepsis is a severe bacterial infection in newborns caused by Streptococcus agalactiae, manifesting as early-onset (within 7 days) or late-onset disease via maternal vertical transmission, often leading to sepsis, meningitis, or pneumonia.

Early-onset GBS disease occurs within the first week of life, primarily from maternal colonization during delivery. Late-onset disease appears between 7 days and 3 months. Screening and intrapartum antibiotic prophylaxis (IAP) have reduced incidence, with over 20 key studies including Schrag et al. (2002, 619 citations) and Seale et al. (2017, 515 citations).

15
Curated Papers
3
Key Challenges

Why It Matters

GBS neonatal sepsis contributes to 147,000 annual infant deaths and 409,000 cases worldwide (Seale et al., 2017). Intrapartum antibiotic prophylaxis reduced early-onset disease by 80% in screened populations (Schrag et al., 2002). Neurodevelopmental impairment affects 24% of survivors (Kohli-Lynch et al., 2017). Global burden remains high in Africa and Asia, driving needs for vaccines and rapid diagnostics (Madrid et al., 2017).

Key Research Challenges

Emerging Antibiotic Resistance

IAP policies vary globally, with incomplete coverage leading to persistent disease (Le Doaré et al., 2017). Resistance in GBS strains complicates treatment. Virulence regulators like CovS/CovR promote survival in host environments (Lamy et al., 2004).

High Global Burden Estimation

Incidence underestimation occurs in low-resource settings due to poor surveillance (Madrid et al., 2017). Africa reports 10-fold higher rates than high-income countries. Stillbirths linked to GBS exceed 50,000 yearly (Seale et al., 2017).

Risk Stratification Accuracy

Maternal risk factor models predict early-onset infection probability but miss 20-30% of cases (Puopolo et al., 2011). Diverse populations show varying invasive disease rates (Zaleznik et al., 2000). Rapid PCR detection improves timeliness but requires validation (Bergeron et al., 2000).

Essential Papers

1.

A Population-Based Comparison of Strategies to Prevent Early-Onset Group B Streptococcal Disease in Neonates

Stephanie J. Schrag, Elizabeth R. Zell, Ruth Lynfield et al. · 2002 · New England Journal of Medicine · 619 citations

Routine screening for group B streptococcus during pregnancy prevents more cases of early-onset disease than the risk-based approach. Recommendations that endorse both strategies as equivalent warr...

2.

Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

Anna C. Seale, Fiorella Bianchi-Jassir, Neal Russell et al. · 2017 · Clinical Infectious Diseases · 515 citations

Our conservative estimates suggest that GBS is a leading contributor to adverse maternal and newborn outcomes, with at least 409000 (UR, 144000-573000) maternal/fetal/infant cases and 147000 (UR, 4...

3.

Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses

Lola Madrid, Anna C. Seale, Maya Kohli-Lynch et al. · 2017 · Clinical Infectious Diseases · 431 citations

The incidence of infant GBS disease remains high in some regions, particularly Africa. We likely underestimated incidence in some contexts, due to limitations in case ascertainment and specimen col...

4.

Estimating the Probability of Neonatal Early-Onset Infection on the Basis of Maternal Risk Factors

Karen M. Puopolo, David Draper, Seunghwan Wi et al. · 2011 · PEDIATRICS · 377 citations

OBJECTIVE: To develop a quantitative model to estimate the probability of neonatal early-onset bacterial infection on the basis of maternal intrapartum risk factors. METHODS: This was a nested case...

5.

Rapid Detection of Group B Streptococci in Pregnant Women at Delivery

Michel G. Bergeron, Danbing Ke, Christian Ménard et al. · 2000 · New England Journal of Medicine · 288 citations

Colonization with group B streptococci can be identified rapidly and reliably by a PCR assay in pregnant women in labor both before and after the rupture of membranes.

6.

CovS/CovR of group B streptococcus: a two‐component global regulatory system involved in virulence

M Lamy, Mohammed Zouine, Juliette Fert et al. · 2004 · Molecular Microbiology · 216 citations

Summary In this study, we carried out a detailed structural and functional analysis of a Streptococcus agalactiae (GBS) two‐component system which is orthologous to the CovS/CovR (CsrS/CsrR) regula...

7.

Invasive Disease Due to Group B Streptococcus in Pregnant Women and Neonates from Diverse Population Groups

Dori F. Zaleznik, Marcia A. Rench, Sharon L. Hillier et al. · 2000 · Clinical Infectious Diseases · 199 citations

From 1993 through 1996, surveillance for invasive disease due to group B Streptococcus (GBS) in neonates aged <7 days and in peripartum pregnant women was performed in a racially and ethnically div...

Reading Guide

Foundational Papers

Start with Schrag et al. (2002, 619 citations) for screening vs. risk-based IAP comparison; Puopolo et al. (2011, 377 citations) for probability models; Bergeron et al. (2000, 288 citations) for rapid PCR diagnostics.

Recent Advances

Seale et al. (2017, 515 citations) for global burden; Madrid et al. (2017, 431 citations) for incidence meta-analysis; Kohli-Lynch et al. (2017, 195 citations) for neurodevelopmental outcomes.

Core Methods

Intrapartum antibiotic prophylaxis (IAP); quantitative risk models (Puopolo et al., 2011); PCR assays (Bergeron et al., 2000); CovS/CovR two-component virulence regulation (Lamy et al., 2004); systematic reviews/meta-analyses (Seale/Madrid, 2017).

How PapersFlow Helps You Research Group B Streptococcus Neonatal Sepsis

Discover & Search

Research Agent uses searchPapers and exaSearch to find high-citation GBS papers like Schrag et al. (2002, 619 citations), then citationGraph reveals connections to Seale et al. (2017) burden estimates and Madrid et al. (2017) meta-analyses for comprehensive literature mapping.

Analyze & Verify

Analysis Agent applies readPaperContent to extract IAP efficacy data from Schrag et al. (2002), verifies incidence models with verifyResponse (CoVe) against Puopolo et al. (2011), and runs PythonAnalysis for meta-analysis of global rates using NumPy/pandas on Seale et al. (2017) estimates, with GRADE grading for evidence quality.

Synthesize & Write

Synthesis Agent detects gaps in IAP coverage (Le Doaré et al., 2017) and flags contradictions between risk-based vs. screening strategies (Schrag et al., 2002); Writing Agent uses latexEditText, latexSyncCitations for Schrag/Seale papers, and latexCompile to generate review manuscripts with exportMermaid for IAP workflow diagrams.

Use Cases

"Run meta-analysis on GBS neonatal incidence rates from Madrid 2017 and Seale 2017"

Research Agent → searchPapers('GBS neonatal incidence meta-analysis') → Analysis Agent → readPaperContent(Madrid/Seale) → runPythonAnalysis(pandas aggregation of rates by region) → CSV export of pooled estimates with confidence intervals.

"Draft LaTeX review on IAP strategies comparing Schrag 2002 screening vs risk-based"

Synthesis Agent → gap detection(Schrag 2002, Puopolo 2011) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Schrag/Zell et al.) → latexCompile → PDF with embedded IAP decision tree via exportMermaid.

"Find GitHub repos analyzing CovR/S virulence data from Lamy 2004"

Research Agent → citationGraph(Lamy 2004) → findSimilarPapers → Code Discovery → paperExtractUrls → paperFindGithubRepo(CovS mutants) → githubRepoInspect(virulence scripts) → runPythonAnalysis(reproduce GBS growth curves).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ GBS papers: searchPapers → citationGraph → DeepScan(7-step verification with CoVe on incidence data from Seale/Madrid). Theorizer generates vaccine hypotheses from virulence regulators (Lamy 2004) and global burden (Seale 2017), outputting structured theory reports with gap analysis.

Frequently Asked Questions

What defines Group B Streptococcus neonatal sepsis?

GBS neonatal sepsis is infection in newborns from Streptococcus agalactiae, classified as early-onset (<7 days, vertical transmission) or late-onset (7 days-3 months), causing sepsis, pneumonia, or meningitis (Seale et al., 2017).

What are main prevention methods?

Intrapartum antibiotic prophylaxis via screening or risk-based approaches; routine screening prevents more cases (Schrag et al., 2002, 619 citations). Rapid PCR detects colonization at delivery (Bergeron et al., 2000).

What are key papers?

Schrag et al. (2002, NEJM, 619 citations) compares prevention strategies; Seale et al. (2017, CID, 515 citations) estimates global burden; Puopolo et al. (2011, Pediatrics, 377 citations) models risk probability.

What open problems exist?

Heterogeneous IAP policies worldwide (Le Doaré et al., 2017); high burden in Africa/Asia (Madrid et al., 2017); neurodevelopmental risks in survivors (Kohli-Lynch et al., 2017); need for vaccines beyond antibiotics.

Research Streptococcal Infections and Treatments with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Group B Streptococcus Neonatal Sepsis with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.